
Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
2
Physical Activity, Vaccination May Protect Against Long COVID
3
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
4
Real-World Data Show Preventive Nirsevimab Reduces Infant RSV Hospitalizations
5